Adding Silver a Solid Move
Source: Michael Ballanger  (4/24/23)
Michael Ballanger of GGM Advisory Inc. reviews the state of the SPX Index, the gold-to-silver ratio, and the current lithium market. More >

As Countries Bolster Defense, Opportunities Emerge
Source: Streetwise Reports  (4/21/23)
Defense stocks are uniquely positioned to enjoy considerable, reliable funding from government contracts. This stability, and the ensuing profitability, increases during times of international political instability. More >

Biotech Co. Secures Majority UK Gov Funding for Phase 3 Trial
Source: Streetwise Reports  (4/19/23)
Phase 3 trials are the last major step in new drug approval and can cost a lot to operate. However, one Canadian pharma company's product is so promising it has convinced the UK government to foot most of the bill. More >

Co.'s New Cell Therapy Shows Positive Effects
Source: Emily Bodnar  (4/19/23)
Disease response and survival rates are impressive in updated results from several studies, noted an H.C. Wainwright & Co. report. More >

Blockchain Co., Vets Group Team Up for App
Source: Streetwise Reports  (4/19/23)
A Vancouver blockchain company is partnering with a leading veterans advocacy group to launch a medical cannabis education and reward application for vets. More >

Oncology Co. Receives Buy Rating for New Drug Trials
Source: Dr. Joseph Pantginis  (4/18/23)
A California drug company is moving into new phases of drug trials targeted at solid tumors, noted an H.C.Wainwright & Co. report. More >

Biotech Rated Outperform Advances Top Drug Candidate
Source: Dr. David Nierengarten  (4/18/23)
The biotech launches another trial of its KIT inhibitor and reports preclinical data for other inhibitors in its pipeline, noted a Wedbush report. More >

Trial Results of New Pneumococcal Vaccine Compelling
Source: Dr. Thomas Shrader   (4/18/23)
Data show the vaccine elicited better immune responses in adults ages 50 and up than the standard of care vaccine, noted a BTIG report. More >

Follow-up Results From T2 Diabetes Trial Positive
Source: Dr. Jonathan Aschoff   (4/14/23)
One year out, overall efficacy was 93% in the patients treated with a new autologous immunotherapy, noted a ROTH Capital Partners report. More >

CEO: Telehealth Co. in 'More Comfortable Cash Position'
Source: Streetwise Reports  (4/14/23)
Telehealth company Reliq Health Technologies Inc. expects to be profitable for the quarter ending in June and initiate a share buyback program this year, its CEO told shareholders this week. More >

Biotech Co. Set To Reach New Highs
Source: Streetwise Reports  (4/13/23)
Algernon Pharmaceuticals Inc. and its subsidiary Algernon NeuroScience have reached a new milestone in a clinical trial investigating the psychedelic drug DMT for the treatment of brain injuries. Click here to learn more about new applications for psychedelics. More >

Phase 3 Trial in Progress of New Ichthyosis Treatment
Source: Dr. Ram Selvaraju  (4/12/23)
Patient recruitment is 50% complete for this multicenter study evaluating a designated orphan drug as treatment for these congenital disorders, noted an H.C. Wainwright & Co. report. More >

Biopharma Co. Appoints Industry Experts in Key Positions
Source: Streetwise Reports  (4/11/23)
Recently, Appili Therapeutics Inc. (APLI.TSX) appointed a new director of non-clinical research and director of new product development. Read to see who these people are, what upcoming catalysts there are for the company, and what experts are saying. More >

Phase 2b Trial of New Drug for Ovarian Cancer Starts
Source: Dr. Joseph Pantginis   (4/11/23)
The investigative, novel small molecule is the lead drug candidate for this U.S. biopharma developing treatments for serious oncological conditions of unmet medical need, noted an H.C. Wainwright & Co. report. More >

Safety Data From One Trial of New Drug Helpful to Another
Source: Ed Arce  (4/5/23)
The investigative compound is atrasentan, currently under evaluation in a Phase 3 study as a treatment for nephropathy, noted an H.C. Wainwright & Co. report. More >

Biotech Co. Will 'Not Look Back' From Here
Source: Clive Maund  (4/5/23)
In light of its recent development of a product that purportedly has the ability to reset damaged DNA, technical analyst Clive Maund takes a look at Resverlogix Corp. More >

Firm Grows Revenue 38% in Q4/22
Source: Andrew Semple  (4/4/23)
The company's material increase in profitability during the quarter is a healthy step toward reaching free cash flow break even status, noted an Echelon Capital Markets report. More >

Target Price on Texas-Based Drug Co. Implies 1,929% ROI
Source: Dr. Jonathan Aschoff   (4/4/23)
This biopharma expects two major catalysts, in the form of Phase 2 clinical trial data readouts, this year, noted a ROTH Capital Partners report. More >

Resverlogix Testing Cure for Covid, the Terrible Spike Protein and Heart Issues
Source: Bob Moriarty  (4/3/23)
In light of Resverlogix Corp.'s testing of a cure for long Covid, Bob Moriarty of 321gold.com reviews the company to tell you why he believes it may be a Buy. More >

New Treatment for Ovarian Cancer Shows Promise
Source: Emily Bodnar  (3/30/23)
Additional trial data also show efficacy of this investigative combination treatment in a difficult to treat patient population, noted an H.C. Wainwright & Co. report. More >

Telehealth Co. Signs Largest Client Yet
Source: Streetwise Reports  (3/30/23)
Onboarding will begin in April for the healthcare system that has more than 1,200 care centers in seven states. More >

Coverage Launched on Drug Co. With 140% Upside
Source: Stefan Quenneville  (3/29/23)
The Canadian specialty pharma, with a proven track record of in-licensing and acquiring late-stage assets, is "poised to grow meaningfully in the coming years," noted an Echelon Capital Markets report. More >

Trial of New Ophthalmic Drug Now Enrolled
Source: Dr. Yi Chen  (3/29/23)
More than the target number of patients was enrolled in this Phase 2 study of an investigative treatment for a serious eye disease, noted an H.C. Wainwright & Co. report. More >

FDA Approval of New Gout Drug Likely, Analyst Says
Source: Yun Zhong  (3/27/23)
Despite a competitor already on the market, the commercial opportunity for this particular treatment is strong, given its advantages, noted a BTIG report. More >

Biotech Improves Efficiency of Its New Immunotherapy
Source: Dr. Jonathan Aschoff  (3/22/23)
The enhancements the company made to its investigative therapy that uses a patient's own immune cells were independently validated, noted a ROTH research report. More >